A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.
epidemiology
interstitial cystitis
prostatitis
symptom flare-up
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
24
4
2019
medline:
19
5
2020
entrez:
24
4
2019
Statut:
ppublish
Résumé
To describe the frequency, intensity and duration of urological chronic pelvic pain syndrome symptom exacerbations ('flares'), as well as risk factors for these features, in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Epidemiology and Phenotyping longitudinal study. Current flare status ('urological or pelvic pain symptoms that are much worse than usual') was ascertained at each bi-weekly assessment. Flare characteristics, including start date, and current intensity of pelvic pain, urgency and frequency (scales of 0-10), were assessed for participants' first three flares and at three randomly selected times when they did not report a flare. Generalized linear and mixed effects models were used to investigate flare risk factors. Of the 385 eligible participants, 24.2% reported no flares, 22.9% reported one flare, 28.3% reported 2-3 flares, and 24.6% reported ≥4 flares, up to a maximum of 18 during the 11-month follow-up (median incidence rate = 0.13/bi-weekly assessment, range = 0.00-1.00). Pelvic pain (mean = 2.63-point increase) and urological symptoms (mean = 1.72) were both significantly worse during most flares (60.6%), with considerable within-participant variability (26.2-37.8%). Flare duration varied from 1 to 150 days (94.3% within-participant variability). In adjusted analyses, flares were more common, symptomatic, and/or longer-lasting in women and in those with worse non-flare symptoms, bladder hypersensitivity, and chronic overlapping pain conditions. In this foundational flare study, we found that pelvic pain and urological symptom flares were common, but variable in frequency and manifestation. We also identified subgroups of participants with more frequent, symptomatic, and/or longer-lasting flares for targeted flare management/prevention and further study.
Identifiants
pubmed: 31012513
doi: 10.1111/bju.14783
pmc: PMC6706296
mid: NIHMS1025346
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-531Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK082345
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082315
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082316
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082344
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082333
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK082316
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK062716
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082325
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082370
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082342
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
J Gen Intern Med. 2001 Oct;16(10):656-62
pubmed: 11679032
J Consult Clin Psychol. 2005 Feb;73(1):168-72
pubmed: 15709844
Int Urogynecol J Pelvic Floor Dysfunct. 2007 May;18(5):551-4
pubmed: 17036170
Arch Sex Behav. 2007 Apr;36(2):301-11
pubmed: 17186130
J Urol. 2007 Apr;177(4):1390-4
pubmed: 17382739
BJU Int. 2008 Jan;101(1):45-51
pubmed: 17868419
Urology. 2009 Apr;73(4):743-6
pubmed: 19193408
Rheum Dis Clin North Am. 2009 May;35(2):339-57
pubmed: 19647147
Urology. 2009 Nov;74(5):983-7, quiz 987.e1-3
pubmed: 19800663
Urology. 2011 Mar;77(3):576-80
pubmed: 21215432
J Urol. 2011 Aug;186(2):540-4
pubmed: 21683389
J Urol. 2013 Jan;189(1):141-5
pubmed: 23164386
J Urol. 2014 Jan;191(1):83-8
pubmed: 23872030
Neurourol Urodyn. 2015 Feb;34(2):188-95
pubmed: 24273163
BJU Int. 2014 Dec;114(6):916-25
pubmed: 24730356
BMC Urol. 2014 Aug 01;14:57
pubmed: 25085007
BMC Urol. 2014 Aug 01;14:58
pubmed: 25085119
J Urol. 2015 May;193(5):1545-53
pubmed: 25623737
Int Urogynecol J. 2015 Jul;26(7):1047-60
pubmed: 25792349
J Urol. 2015 Dec;194(6):1634-41
pubmed: 26192257
J Urol. 2016 Apr;195(4 Pt 1):949-54
pubmed: 26585679
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):132-8
pubmed: 26951713
J Urol. 2017 Sep;198(3):622-631
pubmed: 28373134
J Urol. 2017 Oct;198(4):848-857
pubmed: 28528930
J Urol. 2018 May;199(5):1245-1251
pubmed: 29288643
Ann Acad Med Singapore. 1994 Mar;23(2):129-38
pubmed: 8080219